MiGut: A scalable in vitro platform for simulating the human gut microbiome—Development, validation and simulation of antibiotic‐induced dysbiosis

Microbial Biotechnology · 7 authors, 4 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This study developed and validated a scalable in vitro platform (MiGut) for simulating the human gut microbiome. The platform showed high repeatability and correlated closely with a clinically relevant benchmark model during a 9-week simulation of antibiotic-induced dysbiosis.

Full summary

646 CHARS

This methods study describes the development and validation of the MiGut platform, a scalable in vitro model designed to simulate the human colon microbiome. During antibiotic dosing, both systems showed severe microbiome disruption and subsequent incomplete recovery, with a Pearson's correlation coefficient >0.98 for Bray-Curtis dissimilarity data. The study's primary implication is that MiGut's scalability allows for more complex microbiome-xenobiotic interaction studies with minimal added resources, though this in vitro platform represents preclinical research and its direct applicability to human health requires further investigation.

STUDY TYPE

other

SPECIALTY

preclinical research

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10221534

MiGut: A scalable in vitro platform for simulating the human gut microbiome—Development, validation and simulation of antibiotic‐induced dysbiosis

Microbial Biotechnology

READ THE FULL PAPER

ABSTRACT

Abstract In vitro models of the human colon have been used extensively in understanding the human gut microbiome (GM) and evaluating how internal and external factors affect the residing bacterial populations. Such models have been shown to be highly predictive of in vivo outcomes and have a number of advantages over animal models. The complexity required by in vitro models to closely mimic the physiology of the colon poses practical limits on their scalability. The scalable Mini Gut (MiGut) platform presented in this paper allows considerable expansion of model replicates and enables complex study design, without compromising on in vivo reflectiveness as is often the case with other model systems. MiGut has been benchmarked against a validated gut model in a demanding 9‐week study. MiGut showed excellent repeatability between model replicates and results were consistent with those of the benchmark system. The novel technology presented in this paper makes it conceivable that tens of models could be run simultaneously, allowing complex microbiome‐xenobiotic interactions to be explored in far greater detail, with minimal added resources or complexity. This platform expands the capacity to generate clinically relevant data to support our understanding of the cause‐effect relationships that govern the GM.

CITATION EXPORT

William A Davis Birch, Ines B Moura, Duncan J Ewin et al.. MiGut: A scalable in vitro platform for simulating the human gut microbiome—Development, validation and simulation of antibiotic‐induced dysbiosis. Microbial Biotechnology. (2023). https://doi.org/10.1111/1751-7915.14259

AUTHORS

7 · 4 CENTRES

William A Davis Birch, Ines B Moura, Duncan J Ewin, Mark H Wilcox, Anthony M Buckley, Peter R Culmer, Nikil Kapur

1 School of Mechanical Engineering, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
2 Healthcare‐Associated Infections Group, Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, LS2 9JT, UK
3 Microbiology, Leeds Teaching Hospitals NHS Trust, Old Medical School, Leeds General Infirmary, Leeds, LS1 3EX, UK
4 Microbiome and Nutritional Science Group, Faculty of Food Science and Nutrition, School of Food Science, University of Leeds, Leeds, LS2 9JT, UK